Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with chemotherapy-na? recurrent or metastatic malignant melanoma was recently completed. In Stage 1 of this two-stage clinical trial, 17 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the RECIST criteria. This trial was designed to require at least 1 confirmed partial response in 15 patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 6 of 17 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib for the treatment of hormone refractory prostate cancer who had failed taxane-based chemotherapy was recently completed. In Stage 1 of this two-stage clinical trial, 21 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the RECIST criteria and a prostate-specific antigen (PSA) response of a greater than 50% decline confirmed 3 weeks later. This trial was designed to require a minimum of 1 PSA response in the first 20 evaluable patients in Stage 1 in order to proceed to Stage 2. No patient met the criteria for a PSA response and the median time to PSA or clinical progression was 9 weeks. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the next stage in the clinical trial. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscrip
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:5/20/2013)... May 21, 2013   ... world,s health ministers gather to address the large physical ... and neurological disorders (MNDs) affect 700 million people annually ... (NCD) burden ,Do You Mind?, helps patients, ... each can play to collectively address MNDs , ...
(Date:5/20/2013)... , May 20, 2013  Volcano Corporation (NASDAQ: ... precision guided therapy tools designed to enhance the diagnosis ... announced it will highlight its efforts to expand research ... Flow Reserve (FFR) and iFR ® (Instant Wave-Free ... presentations and events at EuroPCR 2013 in ...
(Date:5/20/2013)... May 20, 2013  B. Braun Medical Inc. ... environmental safety with products, services and education focused ... its innovative Outlook® 400ES and Space Infusion Systems, ... at the American Association of Critical-Care Nurses (AACN) ... Boston Convention Center. ...
Breaking Medicine Technology:Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders 2Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 2Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 3Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 4B. Braun Committed To Improving Patient Safety 2
... Calif., Aug. 31, 2011 Ambry Genetics today ... aCGH technology.  The Ambry CancerArray™ is a high ... with higher probe density coverage in over 400 ... in these functionally important cancer regions. ...
... CYPRESS, Calif., Aug. 31, 2011 Samsung Medison America ... address a growing demand for its expansive line of ... US sales organization and its management in Samsung Medison ... with over 15 years of medical device sales experience. ...
Cached Medicine Technology:Ambry Genetics Announces Launch of Their CancerArray™ Product and Services Utilizing aCGH Technology 2Samsung Medison America Welcomes Brian Keith as Sales General Manager, USA 2
(Date:5/21/2013)... Washington, D.C (PRWEB) May 21, 2013 ... is pleased to announce four transitions for its Board ... Dean of the Western Michigan University School of Medicine, ... Dean of Medical Education at the University of California ... F.A.C.H.E, President/Chief Executive Officer of the Nebraska Medical Center, ...
(Date:5/21/2013)... It took Willie Benitez, a heroin addict who ... on a fifteen year sentence, six months to convince ... him enough to allow Willie to start up an ... intended to name his “drug rehabilitation foundation,” meaning “no-narcotics” ... start up that class. , Early on, when ...
(Date:5/21/2013)... Leading New Jersey real estate agent, Lina ... of her favorite aspects of walkable places is the ... of the current childhood obesity epidemic that plagues the ... living. , A New York Academy of Sciences ... as a key combatant to obesity. The same article ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Dr. James ... and Director of the Sarcoma Division of the John ... New Jersey has been named one of the top ... This Week. Dr. Wittig is one of approximately ... The list was created by surveying thought leaders in ...
(Date:5/21/2013)... The Michigan Lupus Foundation will be ... , June 11th. , Meeting Details: , Tuesday, June ... Center,     Conference Room 5 (Lower Level),     1375 North Main ... to assist people with lupus and their family and ... get a better understanding of this disease and how ...
Breaking Medicine News(10 mins):Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 2Health News:New Board of Directors Leadership for The Match- National Resident Matching Program® 3Health News:Narconon Releases Report on its Very First Narconon Program, the First of 23 Reviews or Evaluations of Results up to 2009 2Health News:Narconon Releases Report on its Very First Narconon Program, the First of 23 Reviews or Evaluations of Results up to 2009 3Health News:Narconon Releases Report on its Very First Narconon Program, the First of 23 Reviews or Evaluations of Results up to 2009 4Health News:Narconon Releases Report on its Very First Narconon Program, the First of 23 Reviews or Evaluations of Results up to 2009 5Health News:New Jersey Realtor, Lina Panza, Advocates Walkable Neighborhoods to Combat Childhood Obesity 2Health News:New Jersey Realtor, Lina Panza, Advocates Walkable Neighborhoods to Combat Childhood Obesity 3Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 2Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 3
... you,re born with, study finds , TUESDAY, June 16 (HealthDay ... blood pressure doesn,t mean you,re doomed to have it, a ... that blood pressure is affected by genes," said Dr. Nora ... North Carolina and lead author of a report on the ...
... Corp. (Nasdaq: HMSY ) today announced that it will ... be held June 17-18, 2009 in New York City. , ... SVP and Chief Financial Officer of HMS Holdings Corp., will present ... , HMS Holdings Corp. (HMS) is the leader in coordination ...
... depicting a biomedical researcher, with breast cancer, in search of ... The Foundation for Biomedical Research (FBR) announced today its ... the 30th Annual Telly Awards competition. Founded in 1978, the ... and cable TV commercials and programs, the finest video and ...
... too, is unclear, expert says, , TUESDAY, June 16 (HealthDay ... according to new research from Spain. , The study found ... fruit (more vitamins, folic acid and fiber and less protein ... lead author, Jaime Mendiola, a researcher at the University of ...
... Nutritional Consultant and Nutrition Expert, Robin De-Ivy Allen conducted a survey ... it possible for a person to eat their way to a ... actually make a person more marketable as an employment candidate? , ... ) , , 68% of survey responders believe that a ...
... Duke University engineers have taken a first step ... combining chemotherapy with heat administered from the end of ... should be technically possible to treat brain tumors without ... surgery, systemic chemotherapy or radiation. The bioengineers designed ...
Cached Medicine News:Health News:Lifestyle May Counter Blood Pressure Genes 2Health News:Lifestyle May Counter Blood Pressure Genes 3Health News:Breast Cancer TV Spot Wins Four Telly Awards 2Health News:Fruits and Veggies May Improve Sperm Quality 2Health News:Nutrition Expert Conducts Survey and Reveals How to Eat Your Way to a New Job 2Health News:Potential for noninvasive brain tumor treatment 2
... membrane parasite soluble lysate ... as antigen. Since this ... than the recombinant kit, ... use two ELISA techniques ...
The Cellabs T. cruzi IgG CELISA is a direct ELISA kit designed to detect antibodies produced during T. cruzi infections (Chagas disease)....
... The dual-electrode SPL defibrillator lead ... design, offering the flexibility and ... Designed for the physician who ... shocking coils, the SPL lead ...
... The Medtronic Subcutaneous Lead ... implanted subcutaneously with the use ... Model 6996T. Improved SQ design ... DFTs, a fast and easy ...
Medicine Products: